![]() |
市場調查報告書
商品編碼
2087687
獸醫分子診斷市場:2026-2032年全球市場預測(依產品類型、技術、動物種類、疾病及最終使用者分類)Veterinary Molecular Diagnostic Market by Product, Technology, Animal Type, Disease Type, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,獸醫分子診斷市場規模將達到 23.5 億美元,複合年成長率為 7.90%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 13.8億美元 |
| 預計年份:2026年 | 14.9億美元 |
| 預測年份 2032 | 23.5億美元 |
| 複合年成長率 (%) | 7.90% |
獸醫分子診斷正成為現代動物醫學的核心領域,因為它能夠以更高的分析靈敏度和更快的速度識別病原體、遺傳標記和抗生素抗藥性決定因素,優於許多培養方法。聚合酵素鏈鎖反應(PCR)、即時定量PCR(qPCR)、逆轉錄PCR、等溫擴增、微陣列和次世代定序(NGS)等技術現已廣泛應用於伴侶動物照護、畜牧生產、馬科動物醫學、野生動物健康管理、水產養殖和肉類用動物生物安全等領域。
快速PCR平台、多重檢測板、攜帶式核酸檢測和基於定序的流行病學技術的融合正在重塑獸醫分子診斷領域。獸醫院和實驗室正從單一病原體檢測轉向能夠區分臨床表現相似的呼吸道、消化道、生殖系統和媒介傳播疾病的多重檢測,從而能夠更快地做出治療、隔離和生物安全方面的決策。
人工智慧 (AI) 正在累積提升獸醫分子診斷的各個方面,例如檢測方法開發、工作流程最佳化、生物資訊學和臨床決策支援。 AI 驅動的引子和探針設計能夠篩檢病原體基因組中的保守和特異性區域,從而加速標靶選擇,降低交叉反應的風險,並幫助實驗室即使在病原體變異的情況下也能快速反應。
由於強勁的寵物消費、完善的參考檢查室網路、大學獸醫醫院以及發展成熟且政府支持的動物疾病監測系統,北美仍然是獸醫分子診斷領域最先進的地區之一。美國受益於國家動物健康檢查室網路等基礎設施,而加拿大的監測系統則支持對牲畜、野生動物和寵物的檢測。墨西哥在畜牧業生產和跨境貿易中扮演著至關重要的角色,這推動了對快速診斷的需求,以確保生物安全和市場進入。
在東協地區,獸醫分子診斷的需求與家禽、生豬、水產養殖以及新興的伴侶動物照護領域密切相關。該地區畜牧業密集,跨國貿易頻繁,因此快速PCR檢測和監測對於禽流感、非洲豬瘟和其他跨境疾病至關重要。此外,東協的檢測實驗室在食品安全、進口管制和出口認證方面也發揮著日益重要的作用。
美國憑藉其在伴侶動物醫療保健方面的大規模醫療費用支出、龐大的標準檢測實驗室規模以及聯邦和州級的動物疫病監測體系,引領這項技術的應用。加拿大則專注於綜合監測和牲畜健康管理,而墨西哥的家禽、牛和豬產業也為快速可靠的檢測提供了支持。巴西作為世界領先的牛肉和家禽出口國,在獸醫分子診斷領域中扮演著至關重要的角色,疾病監測、認證和生物安全是其不可或缺的環節。
產業領導者應優先考慮經臨床檢驗、工作流程高效的分子診斷平台,以應對伴侶動物、牲畜、家禽、水產養殖和馬匹醫學中高負擔疾病的診療。針對呼吸道、消化器官系統、生殖系統和媒介傳播疾病的多參數診斷方案,可透過縮短診斷時間並指導治療、隔離和合理使用抗生素等決策,從而發揮顯著價值。
本執行摘要採用系統性的二手資料研究途徑編寫,重點在於動物健康、感染疾病、診斷和公共政策領域的檢驗資訊來源。主要資訊來源世界動物衛生組織(OIE)、美國疾病管制與預防中心(CDC)、美國農業部(USDA)、美國食品藥物管理局(FDA)、歐盟委員會、歐洲食品安全局(EFSA)、各國動物衛生機構、同行評審期刊、獸醫協會和診斷技術提供者的公開資訊。
獸醫學中的分子診斷正從一項專門的檢查室服務轉變為動物健康、公共衛生、食品安全和生物安全的重要策略組成部分。 PCR、qPCR、等溫擴增和定序技術能夠更快、更準確地檢測日益廣泛的動物群體中的感染疾病、遺傳風險和抗生素抗藥性標記。
The Veterinary Molecular Diagnostic Market is projected to grow by USD 2.35 billion at a CAGR of 7.90% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.38 billion |
| Estimated Year [2026] | USD 1.49 billion |
| Forecast Year [2032] | USD 2.35 billion |
| CAGR (%) | 7.90% |
Veterinary molecular diagnostics is becoming a core pillar of modern animal health because it can identify pathogens, genetic markers, and antimicrobial resistance determinants with high analytical sensitivity and faster turnaround than many culture-based methods. Polymerase chain reaction (PCR), real-time quantitative PCR (qPCR), reverse transcription PCR, isothermal amplification, microarrays, and next-generation sequencing (NGS) are now used across companion animal care, livestock production, equine medicine, wildlife health, aquaculture, and food-animal biosecurity.
Demand is supported by structural disease pressure. The CDC reports that 6 in 10 known infectious diseases in people can spread from animals, while 3 in 4 new or emerging infectious diseases in people originate in animals. This zoonotic risk profile makes veterinary infectious disease testing, syndromic panels, antimicrobial resistance detection, and genomic surveillance strategically important for veterinarians, producers, public health agencies, and diagnostic laboratories.
The market's center of gravity is shifting from reactive testing toward early detection, herd-level surveillance, precision treatment decisions, and integrated One Health monitoring. As pet ownership, livestock intensification, cross-border animal trade, and antimicrobial stewardship requirements expand, veterinary molecular diagnostic solutions are increasingly evaluated on accuracy, speed, workflow efficiency, sample-to-answer automation, regulatory compliance, and interoperability with laboratory information systems.
The veterinary molecular diagnostics landscape is being reshaped by the convergence of rapid PCR platforms, multiplex panels, portable nucleic-acid testing, and sequencing-based epidemiology. Veterinary hospitals and reference laboratories are moving beyond single-pathogen tests to panels that can differentiate clinically similar respiratory, gastrointestinal, reproductive, and vector-borne diseases, enabling faster treatment, isolation, and biosecurity decisions.
Livestock and poultry producers are also adopting molecular testing to reduce economic losses linked to outbreaks, support vaccination strategies, and comply with trade and animal health rules. Diseases such as avian influenza, African swine fever, bovine respiratory disease complex, foot-and-mouth disease, and porcine reproductive and respiratory syndrome have reinforced the value of rapid detection and traceability across farms, transport networks, and processing environments.
A second major shift is decentralization. Point-of-care and near-patient molecular platforms are reducing reliance on distant laboratories for urgent decisions, while cloud-connected instruments improve result reporting and outbreak visibility. At the same time, laboratories continue to invest in automation, extraction-free workflows, high-throughput qPCR, and NGS to manage larger sample volumes and support genomic surveillance.
Artificial intelligence is cumulatively improving veterinary molecular diagnostics across assay development, workflow optimization, bioinformatics, and clinical decision support. AI-enabled primer and probe design can accelerate target selection by screening pathogen genomes for conserved and specific regions, reducing the risk of cross-reactivity and helping laboratories adapt when pathogens mutate.
In sequencing workflows, machine learning supports read classification, variant calling, antimicrobial resistance gene detection, and outbreak clustering. These capabilities are particularly relevant for One Health surveillance because animal, human, and environmental data must be interpreted together to identify transmission pathways and emerging risks.
AI is also changing laboratory operations. Predictive analytics can help forecast testing demand during seasonal respiratory disease, vector-borne disease, or food-animal outbreak cycles. Automated quality-control flags can identify extraction failure, inhibition, contamination patterns, or unusual positivity rates. For veterinarians, AI-assisted interpretation can support evidence-based test selection and antimicrobial stewardship, provided outputs remain transparent, validated, and supervised by qualified professionals.
North America remains one of the most advanced regions for veterinary molecular diagnostics due to strong companion animal spending, established reference laboratory networks, university veterinary hospitals, and government-supported animal disease surveillance. The United States benefits from infrastructure such as the National Animal Health Laboratory Network, while Canada's surveillance ecosystem supports livestock, wildlife, and companion animal testing. Mexico's role in livestock production and cross-border trade strengthens demand for rapid diagnostics that support biosecurity and market access.
Europe is shaped by stringent animal health, food safety, and antimicrobial stewardship expectations. The European Union's Animal Health Law and coordinated surveillance approach encourage harmonized disease monitoring, while major veterinary markets such as Germany, France, Italy, Spain, and the United Kingdom maintain strong demand for PCR, qPCR, and sequencing services in companion animal and production animal settings. Russia's large livestock base and transcontinental geography create continuing need for scalable animal disease diagnostics.
Asia-Pacific is expanding as pet ownership rises, livestock systems modernize, and governments invest in disease surveillance following repeated regional threats such as avian influenza and African swine fever. China, India, Japan, South Korea, and Australia represent distinct demand centers, ranging from large-scale food-animal testing to high-value companion animal diagnostics and advanced biosecurity programs. Latin America, led by Brazil and Mexico, is supported by export-oriented livestock and poultry industries where molecular testing strengthens certification, traceability, and outbreak response. The Middle East is investing in food security, equine health, falcon health, and camel disease diagnostics, while Africa's long-term opportunity is tied to transboundary animal disease control, laboratory capacity building, and One Health programs for zoonotic disease monitoring.
Within ASEAN, demand for veterinary molecular diagnostics is closely tied to poultry, swine, aquaculture, and emerging companion animal care. The region's dense animal production systems and cross-border trade make rapid PCR and surveillance testing important for avian influenza, African swine fever, and other transboundary diseases. ASEAN laboratories are also increasingly relevant to food safety, import controls, and export certification.
The GCC market is shaped by food security strategies, high-value equine and falcon health, camel disease management, and growing companion animal care. Molecular diagnostics can support rapid outbreak response, quarantine decisions, and import screening in countries that depend heavily on animal and food imports. In the European Union, harmonized regulation, antimicrobial resistance monitoring, animal welfare expectations, and veterinary public health programs continue to strengthen demand for validated molecular assays and interoperable laboratory data.
BRICS countries represent a major strategic demand base because they combine large livestock populations, expanding pet care, and government interest in biosecurity. China, India, and Brazil are especially important due to the scale of animal agriculture and the need to protect trade-sensitive supply chains. G7 markets lead in premium companion animal diagnostics, advanced sequencing, laboratory automation, and regulatory quality systems. NATO countries are relevant from a biosecurity perspective because animal disease surveillance can intersect with food supply resilience, military working animal health, and protection against agroterrorism threats.
The United States leads adoption through large companion animal healthcare expenditure, reference laboratory scale, and federal-state animal disease surveillance. Canada emphasizes integrated surveillance and livestock health, while Mexico's poultry, cattle, and swine industries support demand for fast, reliable testing. Brazil is a critical country for veterinary molecular diagnostics because it is a global leader in beef and poultry exports, making disease monitoring, certification, and biosecurity essential.
In Europe, the United Kingdom maintains strong companion animal and equine diagnostic demand, while Germany and France combine advanced veterinary care with major livestock sectors. Italy and Spain are important for companion animals, swine, poultry, and ruminant health. Russia's large agricultural footprint and disease-control needs support continued use of molecular testing for production animals and transboundary disease risks.
China is a central growth market due to its vast swine and poultry industries, expanding pet care sector, and continued emphasis on biosecurity after African swine fever disruptions. India's opportunity is anchored in dairy, poultry, companion animals, and public-sector disease surveillance. Japan and South Korea represent technologically advanced markets with strong quality expectations, aging pet populations, and high diagnostic standards, while Australia's strict biosecurity environment and export-oriented livestock industry make molecular diagnostics essential for early detection, surveillance, and trade confidence.
Industry leaders should prioritize clinically validated, workflow-efficient molecular diagnostic platforms that address high-burden disease categories in companion animals, livestock, poultry, aquaculture, and equine medicine. Multiplex respiratory, gastrointestinal, reproductive, and vector-borne disease panels can deliver strong value when they shorten time to diagnosis and guide treatment, isolation, and antimicrobial stewardship decisions.
Manufacturers and laboratories should invest in automation, contamination control, sample preparation simplification, cold-chain resilience, and connectivity with practice management and laboratory information systems. These capabilities improve throughput, reduce manual error, and support faster reporting during outbreak conditions. Providers should also design solutions that meet regional regulatory expectations and include robust quality-control documentation.
Strategic partnerships with veterinary schools, reference laboratories, public health agencies, producers, and distributors can accelerate adoption. Leaders should also build AI governance into product roadmaps by validating algorithms, documenting performance, protecting data privacy, and ensuring veterinarians remain central to clinical interpretation.
This executive summary is developed using a structured secondary research approach focused on verified sources in animal health, infectious disease, diagnostics, and public policy. Core inputs include publicly available information from organizations such as the World Organisation for Animal Health, the CDC, USDA, FDA, European Commission, EFSA, national animal health agencies, peer-reviewed journals, veterinary associations, and publicly available disclosures from diagnostic technology providers.
The analysis triangulates disease burden, regulatory direction, technology adoption, regional animal health infrastructure, and end-user demand across companion animal, livestock, poultry, equine, aquaculture, and wildlife applications. Market interpretation is grounded in observable drivers such as zoonotic disease risk, antimicrobial resistance monitoring, animal trade requirements, laboratory modernization, and the shift toward molecular and genomic surveillance.
All qualitative insights are reviewed for consistency, plausibility, and relevance to veterinary molecular diagnostics. No unsupported market-size, market-share, or forecast claims are used; the emphasis is on evidence-backed trends, technology adoption patterns, and strategic implications for decision-makers.
Veterinary molecular diagnostics is moving from a specialized laboratory service to a strategic component of animal health, public health, food security, and biosecurity. PCR, qPCR, isothermal amplification, and sequencing technologies are enabling faster and more precise detection of infectious diseases, genetic risks, and antimicrobial resistance markers across a widening set of animal populations.
The strongest opportunities will favor providers that combine validated assays, scalable workflows, regional regulatory alignment, and digital connectivity. AI will further improve assay design, surveillance analytics, and laboratory productivity, but adoption will depend on transparent validation, responsible data governance, and supervised clinical use.
As zoonotic disease risk, livestock trade, pet healthcare expectations, and One Health programs intensify, veterinary molecular diagnostics will remain a high-priority investment area for laboratories, veterinary providers, producers, governments, and diagnostic technology innovators.